Is retatrutide stronger than tirzepatide?

In separate trials, retatrutide produced larger average weight loss (about 24% at 12 mg over 48 weeks in a 338-person phase 2 study) than tirzepatide (about 21% at 15 mg over 72 weeks in a 2,539-person phase 3 study). The trials differ in size, duration, population and phase, so this is a suggestion, not a proven difference. No head-to-head trial has been published.

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors, GLP-1 and GIP. Retatrutide activates three, adding the glucagon receptor, which is thought to raise energy expenditure as well as reduce appetite. Tirzepatide is a licensed medicine in the UK; retatrutide is in phase 3 trials and has no licence anywhere.

Can I get retatrutide instead of tirzepatide in the UK?

No. Tirzepatide is prescription-only and can be prescribed after a clinical assessment. Retatrutide is not licensed, so there is no routine prescribing route outside a clinical trial, and products sold online as retatrutide are unlicensed with no check on their contents.

Do retatrutide and tirzepatide have the same side effects?

Both trials report mainly gastrointestinal effects: nausea, diarrhoea, vomiting and constipation, dose-related and concentrated during escalation. Retatrutide's phase 2 trial additionally reported a heart-rate increase peaking around 24 weeks and skin sensations in some participants. Tirzepatide has a fuller safety record because of its larger trials and licensed use.

Which has the better evidence?

Tirzepatide, by a wide margin: multiple phase 3 trials in thousands of people, a regulatory review, a licence, and real-world use. Retatrutide has one published phase 2 obesity trial and one in type 2 diabetes; the manufacturer has announced headline phase 3 results in press releases, but full peer-reviewed publication and regulatory review are still to come, and no licence exists anywhere as of September 2026.

How do the dosing schedules compare?

Both start low and step up. Tirzepatide's licence runs from 2.5 mg weekly to a maintenance dose of 5, 10 or 15 mg. Retatrutide's phase 2 trial tested 1 to 12 mg weekly, stepping up in four-week intervals. Only tirzepatide has a licensed schedule; retatrutide's figures are trial arms, not a dosing guide.

Will retatrutide replace tirzepatide?

Unknown. If phase 3 trials confirm the phase 2 results and a regulator approves it, retatrutide may become another licensed option. That is likely to be years away in the UK, and the comparison will only be settled by head-to-head trials that do not yet exist.

Why do comparisons between trials mislead?

Different trials enrol different people, run for different lengths, escalate differently and measure at different points. A 48-week phase 2 result and a 72-week phase 3 result are not on the same scale. Only a randomised head-to-head trial answers "which is better" directly.

Retatrutide and tirzepatide compared on mechanism, trial weight loss, side effects, dosing schedules and regulatory status. Why cross-trial comparisons mislead, what a head-to-head trial would need to show, and why one can be prescribed in the UK and the other cannot be lawfully sold at all.

Resources - RESEARCH LITERACY

Retatrutide vs tirzepatide: what the trials show, how they differ, and why one is licensed and one is not

Retatrutide and tirzepatide are both weekly injections from the same manufacturer, both act on gut-hormone receptors to reduce appetite and improve blood sugar, and both produced large weight loss in trials. The differences are real and they matter: tirzepatide acts on two receptors and is a licensed medicine in the UK with phase 3 trials in thousands of people behind it; retatrutide acts on three, has one published phase 2 obesity trial in 338 people, and has no licence anywhere. This article compares them on mechanism, trial results, side effects, dosing schedules and regulatory status, explains why the comparison everyone wants to make, "which one loses more weight", cannot be answered from the trials that exist, and sets out what each one means for someone in the UK. It does not recommend either.

Mechanism: two receptors versus three

Tirzepatide is a dual agonist. It activates the GLP-1 receptor, the target of semaglutide, which slows stomach emptying, improves insulin release and reduces appetite through the brain, and the GIP receptor, another gut-hormone receptor whose contribution appears to enhance the weight and blood-sugar effects and possibly reduce nausea. Retatrutide adds a third: the glucagon receptor. Glucagon normally raises blood sugar, which sounds like the wrong direction for a diabetes and obesity drug, but glucagon-receptor activation is thought to increase energy expenditure and fat oxidation in the liver. Paired with the appetite-suppressing effects of the other two, the theory is that retatrutide pushes weight down from both sides, less energy in and more energy out.

Whether the third receptor is the reason for retatrutide's larger trial numbers is plausible but not proven. The mechanism explains why the drug might work harder; only trials show whether it does, and at what cost in side effects.

Trial results: the numbers and why they are not comparable

The tirzepatide figure comes from SURMOUNT-1, a phase 3 trial of 2,539 adults with obesity or overweight and a weight-related condition, without diabetes, run for 72 weeks. Average weight change was about 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg weekly, against about 3.1% on placebo. The retatrutide figure comes from a phase 2 trial of 338 similar adults run for 48 weeks: about 8.7%, 17.1%, 22.8% and 24.2% at 1, 4, 8 and 12 mg weekly, against about 2.1% on placebo, with weight still falling at 48 weeks in the higher-dose groups.

Put side by side, 24.2% at 48 weeks looks bigger than 20.9% at 72 weeks, and it is tempting to conclude retatrutide is stronger. The trials do not support that conclusion, for reasons that apply to every cross-trial comparison in this class. The populations were different, even if the entry criteria looked similar. The durations were different, and weight loss curves flatten at different points. The dose escalations were different. Phase 2 trials, being smaller, produce estimates with wider uncertainty, and their results often shrink in phase 3. And the trials were run at different times with different background care. What the two results support is a narrower statement: the phase 2 averages sit in the same range as, or numerically above, tirzepatide's phase 3 averages, which is why it is being taken seriously. Whether it is actually more effective in the same people over the same time is unknown until someone runs that trial.

Side effects: the same family, with additions

Both drugs produce the class side effects: nausea, diarrhoea, vomiting and constipation, mostly mild to moderate, dose-related, and clustered around dose increases. Both trials saw a minority of participants stop because of them, more at higher doses. Tirzepatide's licence adds the less common risks that a larger evidence base reveals: gallbladder disease, pancreatitis, low blood sugar when combined with certain diabetes medicines, and effects on absorption of oral medicines.

Retatrutide's phase 2 trial reported two findings that stand out against tirzepatide's record, whose licence notes only a small average heart-rate rise: an increase in heart rate that peaked around 24 weeks and lessened by 48, and skin sensations described as tingling or heightened sensitivity in some participants. Whether these are specific to glucagon-receptor activation, dose-related, or artefacts of a smaller trial is one of the questions phase 3 exists to answer. The honest comparison on safety is that tirzepatide is well characterised and retatrutide is not yet.

Dosing schedules: one is a licence, one is a set of trial arms

Tirzepatide's UK licence specifies a schedule: 2.5 mg weekly for four weeks, then 2.5 mg steps at intervals of at least four weeks, to a maintenance dose of 5, 10 or 15 mg chosen by the prescriber. That schedule was set by trials and reviewed by a regulator, and a prescriber adjusts within it for each patient. Retatrutide's numbers are trial arms: 1, 4, 8 and 12 mg weekly maintenance, reached by four-week steps from 2 or 4 mg. They describe what the study did, not what anyone should do, and there is no licensed strength, no licensed device and no prescriber who can set a dose within a schedule that does not exist. Our separate articles on tirzepatide and retatrutide set out each in full.

Regulatory status in the UK

Tirzepatide is a prescription-only medicine, licensed for type 2 diabetes and for weight management, recommended by NICE in December 2024 with a phased NHS rollout from mid-2025, and otherwise supplied only against a prescription after a clinical assessment. It cannot be advertised to the public, and unlicensed copies sold online are unlawful. Retatrutide has no marketing authorisation in the UK or anywhere else and is in phase 3 trials; the manufacturer has announced headline phase 3 results in press releases, but full peer-reviewed publication and any regulatory review are still to come. There is no routine prescribing route to it outside a trial, and anything sold as retatrutide is an unlicensed product whose contents no regulator has checked. The MHRA has seized unlicensed retatrutide and tirzepatide products in quantity and made arrests on suspicion of offences under the Human Medicines Regulations.

Blood sugar, and what the diabetes trials add

Both drugs were studied in type 2 diabetes as well as obesity, and the diabetes trials sharpen the comparison in one respect. Tirzepatide's SURPASS programme, several large phase 3 trials, showed reductions in HbA1c larger than those of comparators including semaglutide 1 mg, alongside weight loss, and formed the basis of its first licence. Retatrutide's phase 2 diabetes trial, published in the Lancet in 2023, showed dose-related HbA1c and weight reductions over 36 weeks in 281 people, again against placebo and a licensed comparator. The pattern is the same as in obesity: retatrutide's early numbers are at least as good, and tirzepatide's are far better established. For someone whose main concern is blood sugar, the practical distinction is simpler still, because only one of the two has a licence covering it.

The glucagon question

The third receptor is retatrutide's distinguishing feature and also its main open question. Glucagon-receptor activation is thought to raise energy expenditure, which is the intended benefit, but glucagon also acts on the heart, the liver and blood sugar in ways that a dual agonist does not. The heart-rate increase seen in the phase 2 trial is consistent with that pharmacology, and it is the kind of signal that phase 3 trials, with thousands of participants and cardiovascular monitoring, are designed to characterise. Until those results are published in full, the fair statement is that retatrutide may buy extra weight loss with an extra receptor whose long-term effects in this setting are not yet described. Tirzepatide, without that receptor, has a longer and larger safety record. Neither fact is an argument for or against either drug; they are the reasons regulators sequence things the way they do.

What a real comparison would need

A randomised head-to-head trial: the same population, randomised to one drug or the other at their respective maintenance doses, followed for the same period, with weight, side effects, discontinuations and cardiovascular measures recorded alongside. Such a trial exists for tirzepatide against semaglutide: SURMOUNT-5 randomised adults with obesity but without diabetes to one or the other for 72 weeks and reported greater average weight loss in the tirzepatide group, measured directly rather than inferred from separate studies. That is the standard of evidence the retatrutide question is waiting for, and a manufacturer with both drugs has every incentive to run it once retatrutide is licensed. Nothing equivalent has been published for retatrutide against tirzepatide. Until it is, the question in this article's title has a two-word answer: not yet.

What this means in practice

For someone in the UK, tirzepatide is a licensed medicine with a fuller evidence base and a regulator-reviewed schedule; whether it is appropriate for any individual is a clinical decision, not one this article can inform. Retatrutide is a promising investigational drug that may become a licensed option if its phase 3 results hold up to publication and regulatory review, and is not lawfully available in the meantime. Treating the phase 2 number as a reason to seek out an unlicensed vial trades a documented medicine for an unverified powder on the strength of a comparison the trials cannot actually make. The decision about any of these medicines belongs with a prescriber, who will be working from the licence rather than the headline.

This article is educational content only and is not medical advice or a recommendation to use any medicine. Tirzepatide is a prescription-only medicine; retatrutide is unlicensed and investigational. Trial figures are reported as trial figures and are not instructions for use. Anyone considering treatment for weight or blood sugar should speak to a GP, pharmacist or other qualified prescriber. Vivera Education sells nothing.

Frequently asked

Is retatrutide stronger than tirzepatide?: In separate trials, retatrutide produced larger average weight loss (about 24% at 12 mg over 48 weeks in a 338-person phase 2 study) than tirzepatide (about 21% at 15 mg over 72 weeks in a 2,539-person phase 3 study). The trials differ in size, duration, population and phase, so this is a suggestion, not a proven difference. No head-to-head trial has been published.
What is the difference between retatrutide and tirzepatide?: Tirzepatide activates two receptors, GLP-1 and GIP. Retatrutide activates three, adding the glucagon receptor, which is thought to raise energy expenditure as well as reduce appetite. Tirzepatide is a licensed medicine in the UK; retatrutide is in phase 3 trials and has no licence anywhere.
Can I get retatrutide instead of tirzepatide in the UK?: No. Tirzepatide is prescription-only and can be prescribed after a clinical assessment. Retatrutide is not licensed, so there is no routine prescribing route outside a clinical trial, and products sold online as retatrutide are unlicensed with no check on their contents.
Do retatrutide and tirzepatide have the same side effects?: Both trials report mainly gastrointestinal effects: nausea, diarrhoea, vomiting and constipation, dose-related and concentrated during escalation. Retatrutide's phase 2 trial additionally reported a heart-rate increase peaking around 24 weeks and skin sensations in some participants. Tirzepatide has a fuller safety record because of its larger trials and licensed use.
Which has the better evidence?: Tirzepatide, by a wide margin: multiple phase 3 trials in thousands of people, a regulatory review, a licence, and real-world use. Retatrutide has one published phase 2 obesity trial and one in type 2 diabetes; the manufacturer has announced headline phase 3 results in press releases, but full peer-reviewed publication and regulatory review are still to come, and no licence exists anywhere as of September 2026.
How do the dosing schedules compare?: Both start low and step up. Tirzepatide's licence runs from 2.5 mg weekly to a maintenance dose of 5, 10 or 15 mg. Retatrutide's phase 2 trial tested 1 to 12 mg weekly, stepping up in four-week intervals. Only tirzepatide has a licensed schedule; retatrutide's figures are trial arms, not a dosing guide.
Will retatrutide replace tirzepatide?: Unknown. If phase 3 trials confirm the phase 2 results and a regulator approves it, retatrutide may become another licensed option. That is likely to be years away in the UK, and the comparison will only be settled by head-to-head trials that do not yet exist.
Why do comparisons between trials mislead?: Different trials enrol different people, run for different lengths, escalate differently and measure at different points. A 48-week phase 2 result and a 72-week phase 3 result are not on the same scale. Only a randomised head-to-head trial answers "which is better" directly.